4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer
4D Path’s QPOR™ Platform Selected to Predict Patients’ Responses to Therapy Newton, Massachusetts – January 22, 2026 – 4D Path, a company dedicated to personalizing…